Purpose: An analytical and experimental study of split shape dose calculation correction by adjusting the position of the on-axis round leaf end position is presented. We use on-axis corrected results to predict off-axis penumbra region dosimetric performance in an intensity-modulated radiation therapy treatment planning system.
Materials And Methods: The precise light-field edge position (X(tang.p)) was derived from the on-axis 50% dose position created by using the nominal light field for geometric and mathematical manipulation. Leaf position (X(mlc.p)) could be derived from X(tang.p) by defining in the treatment planning system for monitor unit calculation. On-axis offset (correction) could be obtained from the position corresponding to 50% of the central axis dose minus the X(mlc.p) position. The off-axis 50% dose position can then be derived from the on-axis 50% dose position.
Results: The monitor unit calculation of the split shape using the on-axis rounded leaf end MLC penumbra region could provide an under-or overdose of 7.5% per millimeter without an offset correction. When using the on-axis rounded leaf end offset correction to predict the off-axis dose, the difference between the off- and on-axis 50% dose position is within ±1.5 mm.
Conclusions: It is possible to achieve a dose calculation within 0.5% error for an adjusted MLC leaf edge location in the treatment planning system with careful measurement and an accurate on-axis offset correction. Dose calculations located at an off-axis spilt shape region should be used carefully due to noncorrectable errors which were found to be up to 10%.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3821896 | PMC |
http://dx.doi.org/10.1155/2013/461801 | DOI Listing |
Bioconjug Chem
January 2025
Department of Pharmacology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104-5127, United States.
Red blood cells (RBCs) serve as natural transporters and can be modified to enhance the pharmacokinetics and pharmacodynamics of a protein cargo. Affinity targeting of Factor IX (FIX) to the RBC membrane is a promising approach to improve the (pro)enzyme's pharmacokinetics. For RBC targeting, purified human FIX was conjugated to the anti-mouse glycophorin A monoclonal antibody Ter119.
View Article and Find Full Text PDFPurpose: Outcomes for patients with advanced sarcomas are poor and there is a high unmet need to develop novel therapies. The purpose of this phase I study was to define the safety and efficacy of botensilimab (BOT), an Fc-enhanced anti-cytotoxic lymphocyte-association protein-4 antibody, plus balstilimab (BAL), an anti-PD-1 antibody, in advanced sarcomas.
Methods: BOT was administered intravenously (IV) at 1 mg/kg or 2 mg/kg once every 6 weeks in combination with BAL IV at 3 mg/kg once every 2 weeks for up to 2 years.
Microbiol Spectr
January 2025
National Key Laboratory of Agricultural Microbiology, Hubei Hongshan Laboratory, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, Hubei, China.
Unlabelled: Bovine herpesvirus (BoHV) infection poses a significant threat to the healthy development of the cattle industry. BoHV-1 primarily causes infectious bovine rhinotracheitis, while BoHV-5 is associated with bovine necrotic meningoencephalitis. These two pathogens not only exhibit a high correlation in antigenicity and genetic background but, more importantly, can establish latent infections within the bovine ganglion.
View Article and Find Full Text PDFDrug Dev Res
February 2025
Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, Zhejiang University of Technology, Hangzhou, Zhejiang, China.
Diabetes nephropathy (DN) is a severe diabetic chronic microvascular complication and the major cause of end-stage renal disease (ESRD). Our study aimed to investigate the effects of isoliquiritigenin (ISL) a natural flavonoid compound on DN and to explore the underlying mechanisms. The db/db mice were received intragastric treatments of ISL (5, 10, or 20 mg/kg), vehicle or positive drug metformin (300 mg/kg) once a day for 12 weeks, and the db/m mice treated with vehicle were used as controls.
View Article and Find Full Text PDFInt J Chron Obstruct Pulmon Dis
January 2025
School of Translational Medicine, Monash University, Melbourne, VIC, Australia.
Purpose: Oral corticosteroids (OCS) are recommended for the treatment of exacerbations in people with COPD; however, high cumulative lifetime doses (≥1000mg prednisolone-equivalent) are associated with adverse health effects. This issue is well defined in asthma but is less well understood in COPD. The aim of this study was to examine cumulative OCS dispensed to people with COPD over 12 months.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!